Hypertension  >>  emricasan (IDN 6556)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
emricasan (IDN 6556) / Amerimmune
NCT02230683: A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension

Completed
2
23
US
IDN-6556, emricasan, PF-013491390
Conatus Pharmaceuticals Inc.
Liver Cirrhosis, Hepatic Cirrhosis, Portal Hypertension
05/15
06/15
ENCORE-PH, NCT02960204 / 2015-004473-32: Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension

Checkmark Top-line data of ENCORE-PH trial in NASH cirrhosis
Dec 2018 - Dec 2018: Top-line data of ENCORE-PH trial in NASH cirrhosis
Completed
2
263
Europe, US
Emricasan, Placebo
Histogen
Cirrhosis, Portal Hypertension, Non-alcoholic Steatohepatitis
10/18
04/19
NCT04806750: Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension

Completed
2
263
NA
Emricasan, Placebo
Histogen
Cirrhosis, Portal Hypertension, Non-alcoholic Steatohepatitis
10/18
04/19

Download Options